> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Opdivo CheckMate Trial Misses Endpoint
- URL: https://www.fdaweb.com/opdivo-checkmate-trial-misses-endpoint/
- Published: 2019-07-25T12:00:00.000Z
- Updated: 2026-09-15T01:40:16.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5144624

Bristol-Myers Squibb says that part 2 of the Phase 3 CheckMate-227 trial did not meet the primary endpoint of overall survival with its Opdivo (nivolumab) plus chemotherapy versus chemotherapy in patients with first-line non-squamous non-small cell lung cancer, regardless of PD-L1 status. The company [says](https://news.bms.com/press-release/rd-news/bristol-myers-squibb-provides-update-part-2-checkmate-227?ref=fdaweb.com) no new safety signals were observed in the trial. “While this is not the outcome we had hoped for, the Opdivo plus chemotherapy one-year landmark overall survival in the non-squamous population was consistent with the experimental arms in previously-reported trials of IO/chemotherapy combination regimens,” says BMS oncology development head **Fouad Namouni**.